Malignant fibrous neoplasms of long bones: analysis of the surveillance, epidemiology, and end results database from 1973 to 2015

Yiting Huang†, Jianqiao Hong†, Jiahong Meng², Haobo Wu², Mingmin Shi², Shigui Yan²* and Wei Wang²*

Abstract

Background: Malignant fibrous neoplasms (MFN) of long bones are rare lesions. Moreover, the prognostic determinants of MFN of long bones have not been reported. This study aimed to present epidemiological data and analyse the prognostic factors for survival in patients with MFN.

Materials and methods: The Surveillance, Epidemiology, and End Results (SEER) programme database was used to screen patients with malignant fibrous neoplasms (MFN) of long bones from 1973 to 2015, with attention to fibrosarcoma, fibromyxosarcoma, periosteal fibrosarcoma and malignant fibrous histiocytoma. The prognostic values of overall survival (OS) and cancer-specific survival (CSS) were assessed using the Cox proportional hazards regression model with univariate and multivariate analyses. The Kaplan–Meier method was used to obtain OS and CSS curves.

Results: A total of 237 cases were selected from the SEER database. Malignant fibrous histiocytoma was the most common form of lesion in long bones. Multivariate analysis revealed that independent predictors of OS included age, stage, tumour size and surgery. Age, stage, tumour size and surgery were also independent predictors of CSS. Additionally, the most significant prognostic factor was whether metastasis had occurred at the time of initial diagnosis.

Conclusion: Among patients with MFN of long bones, age (> 60 years), tumour size (> 10 cm), distant stage, and non-surgical treatment are factors for poor survival.

Keywords: Malignant fibrous neoplasms (MFN), Fibrosarcoma, Fibromyxosarcoma, Periosteal fibrosarcoma, Malignant fibrous histiocytoma, Long bones, Prognosis

Background

Malignant fibrous neoplasms (MFN) are very rare malignant tumours of long bones. These tumours include fibrosarcoma, fibromyxosarcoma, periosteal fibrosarcoma and malignant fibrous histiocytoma (MFH) according to classification from the SEER database. Malignant fibrous neoplasms most commonly arise from the extremities [1], occasionally from the nasal cavity and paranasal sinuses [2], and rarely from long bone.

MFH was first described by O’Brien in 1963 [3] and by Kauffman and Stout (Histiocytic tumors (fibrous xanthoma and histiocytoma) in children in 1961 [4]. It was the most common soft tissue sarcoma [5]. Fibrosarcoma of long bone (LBFS) is another neoplasm in this region that exhibits nonspecific symptoms such as pain. The final diagnosis of this tumour is based on histopathology and immunohistochemistry [6].

Malignant tumours of the long bones are challenging with regard to improving patient survival [7]. Few studies have reported the complications associated with
surgical resection. Therefore, it remains unresolved whether a uniform treatment strategy could be beneficial to all patients.

Here, we present an epidemiologic analysis of MFN of long bone using the U.S. National Cancer Institute’s SEER database from 1973 to 2015. No previous study has specifically performed an in-depth analysis of cases with MFN of long bones using the database. We analysed 237 cases of MFN of long bones from 18 SEER registries, representing the largest cohort of patients with MFN of long bones studied to date. Our analysis includes demographic and clinicopathologic features of this rare neoplasm, along with its survival outcomes.

Materials and methods
Frequency and survival data were obtained from the SEER 18 dataset from 1973 to 2015. SEER had considerably fewer participating registries in the early years, and the number gradually increased relatively recently to reach 18. The cases included in this dataset were diagnosed between 1973 and 2015. Fibrosarcoma cases were screened using the morphological codes for fibrosarcoma (8810/3), fibromyxosarcoma (8811/3), periosteal fibrosarcoma (8812/3), and malignant fibrous histiocytoma (8830/3). Based on the topographical codes, cases with MFN were restricted to the long bone, namely, the long bones of the upper limb, scapula, and associated joints (C40.0), as well as the long bone of the lower limb and associated joints (C40.2).

Frequency data were stratified and analysed by age, gender, race, grade, tumour size, SEER extent of disease, and treatment strategy. SEER extent of disease is categorized into localized, regional, and distant disease. Localized tumour, regional tumour and distant disease are defined as previously reported [8–11]. Five-year survival rates were calculated using Kaplan-Meier analysis, calculating overall survival (OS) and calculating disease-specific survival (CSS) rates [12]. SEER*Stat 8.1.5 software (National Cancer Institute, Bethesda, MD) and Microsoft Excel 2013 (Microsoft Corp., Redmond, WA) were used to process the data. Statistical Product and Service Solutions (SPSS) 24th edition was used to yield Kaplan-Meier curves and CSS rates. Probability values (p values) < 0.05 were considered statistically significant for all tests.

Results
The demographic characteristics of the 237 patients with MFN of the long bones identified in the SEER database are displayed in Table 1. The specific histopathological diagnosis was fibrosarcoma (21.5%), fibromyxosarcoma (1.7%), periosteal fibrosarcoma (5.1%), and malignant fibrous histiocytoma (71.7%).

Histologically, 55.3% of cases were high grade, 12.2% were low grade, and 32.5% were an unknown tumour grade. More than half (50.2%) of the tumours were at less than 5 cm in size. The extent of disease showed that the majority presented with locally invasive disease (38.4%). Forty-six patients (19.4%) had developed metastasis at presentation. Most patients were diagnosed first with malignant primary tumours (87.8%). After diagnosis, 75.9% of patients underwent surgical treatment and 56.5% of the patients underwent chemotherapy. A total of 160 patients (67.5%) died. The OS rates of the entire cohort at 5 and 10 years were 39.7 and 22.8%, respectively. The CSS rates at 5 and 10 years were 60.3 and 56.5%, respectively.

The 5- and 10-year OS rates for patients with fibrosarcoma of long bones were 31.4 and 11.8%, respectively, and the respective 5- and 10-year CSS rates were 62.7 and 58.8%. For patients with malignant fibrous histiocytoma of long bones, the OS rates were 40.6 and 23.5% and the CSS rates were 58.8 and 55.3%, respectively (Table 1).

Univariate and multivariate analysis of parameters that influence overall survival (OS) and cancer-specific survival (CSS) are illustrated in Tables 2 and 3.

For both OS and CSS, race, gender, decade of diagnosis and tumour type showed no significant effect on survival (p > 0.05; Tables 2 and 3). Univariate survival analysis revealed that older age (age > 60 years) was significantly associated with a worse OS (HR = 7.381, p = 0.001; Table 2; Fig. 1a) and CSS (HR = 3.569, p = 0.032; Table 3; Fig. 2a). Tumour size (> 10 cm) was significantly associated with a worse OS (HR = 4.714, p < 0.001; Table 2; Fig. 1e) and CSS (HR = 7.595, p < 0.001; Table 3; Fig. 2e). Tumour sequence (second) was significantly associated with a worse OS (HR = 1.618, p = 0.031; Table 2) but a higher CSS (HR = 0.042, p = 0.023; Table 3). The stage (distant) was significantly associated with a worse OS (HR = 5.383, p < 0.001; Table 2; Fig. 1f) and CSS (HR = 5.383, p < 0.001; Table 3; Fig. 2f). Radiotherapy was significantly associated with a worse OS (HR = 1.684, p = 0.003; Table 2; Fig. 1d) and CSS (HR = 1.652, p = 0.02; Table 3; Fig. 2d). Surgery was significantly associated with a better OS (HR = 0.267, p < 0.001; Table 2; Fig. 1b) and CSS ((HR = 0.267, p = 0.226; Table 3; Fig. 2b). Chemotherapy was significantly associated with a better OS (HR = 0.688, p = 0.023; Table 2; Fig. 1c) but not with CSS (HR = 0.226, p < 0.001; Table 3; Fig. 2c).

Upon multivariate analysis of all patients (Table 2), age (> 60 years vs < 16 years, HR = 5.688; p = 0.004; 40–60 years vs < 16 years, HR = 3.81; p = 0.027), stage (distant vs. localized, HR = 3.917, p < 0.001), tumour size (> 10 cm vs < 5 cm, HR = 4.051; p = 0.001; 5–10 cm vs < 5 cm, HR = 2.335; p = 0.034), and surgery (HR = 0.397; p < 0.001) were independent predictors of OS.
| Variables                         | Number (%)     | Total |
|----------------------------------|----------------|-------|
| Sex                              |                |       |
| Female                           | 19 (37.3%)     | 109 (46.0%) |
| Male                             | 32 (62.7%)     | 128 (54.0%) |
| Age                              |                |       |
| ≤16                              | 1 (2.0%)       | 12 (5.1%) |
| 17–39                            | 11 (21.6%)     | 42 (17.7%) |
| 40–60                            | 16 (31.4%)     | 73 (30.8%) |
| >60                              | 23 (45.1%)     | 110 (46.4%) |
| Tumor grade                      |                |       |
| Unknown                          | 7 (13.7%)      | 77 (32.5%) |
| Low                              | 18 (35.3%)     | 29 (12.2%) |
| High                             | 26 (51.0%)     | 131 (55.3%) |
| Tumor Size                       |                |       |
| <5 cm                            | 27 (52.9%)     | 119 (50.2%) |
| 5 cm-10                          | 8 (15.7%)      | 26 (11.0%) |
| >10                              | 13 (25.5%)     | 61 (25.7%) |
| Stage                            |                |       |
| Unknown                          | 4 (7.8%)       | 16 (6.8%) |
| Local                            | 23 (45.1%)     | 91 (38.4%) |
| Region                           | 16 (31.4%)     | 84 (35.4%) |
| distant                          | 8 (15.7%)      | 46 (19.4%) |
| Surgery                          |                |       |
| No                               | 13 (19.4%)     | 56 (23.6%) |
| Yes                              | 38 (74.5%)     | 180 (75.9%) |
| Race recode                      |                |       |
| Other                            | 4 (7.8%)       | 16 (6.8%) |
| White                            | 39 (76.5%)     | 195 (82.3%) |
| Black                            | 8 (15.7%)      | 26 (11.0%) |
| Decade of diagnosis              |                |       |
| 1970s                            | 8 (15.7%)      | 22 (9.3%) |
| 1980s                            | 7 (13.7%)      | 40 (16.9%) |
| 1990s                            | 6 (11.8%)      | 44 (18.6%) |
| 2000s                            | 17 (33.3%)     | 94 (39.7%) |
| 2010s                            | 13 (25.5%)     | 37 (15.6%) |
| Stage                            |                |       |
| Unknown                          | 4 (7.8%)       | 11 (6.5%) |
| Local                            | 23 (45.1%)     | 91 (38.4%) |
| Region                           | 16 (31.4%)     | 84 (35.4%) |
| distant                          | 8 (15.7%)      | 46 (19.4%) |
| Surgery                          |                |       |
| No                               | 13 (19.4%)     | 56 (23.6%) |
| Yes                              | 38 (74.5%)     | 180 (75.9%) |
The results of the multivariate analysis of the parameters that influence CSS are presented in Table 3. Age (>60 years vs <16 years, HR = 3.863; 95% CI, 1.14–13.091; \( p = 0.03 \)), stage (distant vs. localized, HR = 4.401, 95% CI, 2.47–7.841, \( p < 0.001 \)), tumour size (>10 cm vs <5 cm, HR = 3.075; 95% CI, 1.092–8.659; \( p = 0.033 \); 5–10 cm vs <5 cm, HR = 2.335; 95% CI, 1.065–5.124; \( p = 0.034 \)), and surgery (HR = 0.318; 95% CI, 0.191–0.527; \( p < 0.001 \)) were independent predictors of CSS.

**Discussion**

MFN are rare malignant tumours. Attention was paid to fibrosarcoma, fibromyxosarcoma, periosteal fibrosarcoma and malignant fibrous histiocytoma. These tumours can infiltrate adjacent tissues and metastasize distally [13–19]. However, the outcome and prognosis of patients with MFN of long bones have not been reported because of its rarity. To our knowledge, the current study is the first to report the prognostic factors that affect the survival of patients with MFN of long bones using multivariate regression analysis.

In the current study, we identified 237 cases of malignant fibrous neoplasms of long bone based on the SEER database from 1973 to 2015. The OS and CSS rates at 5 years were 39.7 and 60.3%, respectively, while the previous study results showed that the OS and CSS of sinonasal fibrosarcoma were 71.7 and 77.8%, respectively [13].

Although malignant fibrous histiocytoma (MFH) ceased to be recognised as an entity in the 2013 edition of the WHO classification of bone and soft tissue tumours [20], undifferentiated high-grade pleomorphic sarcoma is listed as a new synonym for MFH of bone, still with the same code 8830/3, in the recently published ICD-O-3.2. However, the registrations of undifferentiated high-grade pleomorphic sarcoma of bone still decreased in the seer database. This might explain the recent decrease in registrations of MFH. Therefore, this study was of more than purely historical interest.

**Survival by age**

We observed different survival rates by age at diagnosis in many studies [14]. In contrast, we found a higher risk of poor OS in the elder group. In the multivariate analysis of OS for patients aged 17–39 years the HR was 2.765 (\( P = 0.098 \)), for those aged 40–60 years the HR was 3.81 (\( P = 0.027 \)), and for those aged >60 years the HR was 5.688 (\( P = 0.004 \)). We also found a higher risk of poor CSS in the elder group. In the multivariate analysis of CSS for those aged >60 years, the HR was 3.863 (\( P = 0.03^* \)).

### Table 1 Clinical characteristics of patients with MFN of long bones (Continued)

| Variables          | Unknown | Radiotherapy | Chemotherapy | Dead | Tumor sequence | 5-year OS rate | 5-year CSS rate | 10-year OS rate | 10-year CSS rate |
|--------------------|---------|--------------|--------------|------|----------------|----------------|----------------|----------------|----------------|
| Fibrosarcoma (NOS) | N=51    | 0 (0.0%)     | 0 (0.0%)     | 0 (0.0%) | 1 (0.6%)     | 31.40%          | 62.70%          | 11.80%          | 58.80%          |
| Fibromyxosarcoma   | N=4     | 0 (0.0%)     | 0 (0.0%)     | 0 (0.0%) | 1 (0.6%)     | 50.00%          | 75.00%          | 50.00%          | 75.00%          |
| Periosteal fibrosarcoma | N=12 | 0 (0.0%)     | 0 (0.0%)     | 0 (0.0%) | 1 (0.6%)     | 58.30%          | 66.70%          | 50.00%          | 58.30%          |
| Malignant fibrous histiocytoma | N=170 | 1 (0.6%)     | 1 (0.6%)     | 1 (0.6%) | 1 (0.6%)     | 40.60%          | 58.80%          | 23.50%          | 55.30%          |
| Total              | N=181   | 1 (0.4%)     | 1 (0.4%)     | 1 (0.4%) | 1 (0.4%)     | 39.70%          | 56.50%          | 22.80%          | 56.50%          |

*Abbreviations: CSS Cancer-specific survival, OS Overall survival, MFN Malignant fibrous neoplasms*
Survival by gender, race and decade of diagnosis

Our results were consistent with previous results where no differences in survival by gender, or race but not decades were founded [21]. The differences of decades might be caused by the primary site of long bone or small bone.

Table 2: Univariate and multivariate analyses for OS for patients identified in the SEER Program database from 1973 to 2015

| Variables                  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | p-value             | Hazard ratio (95% CI) |
|                            |                     | p-value               | Hazard ratio (95% CI) |
| Age                        | 1                   | 1                     | 1                     |
| ≤16                        | 1                   | 1                     | 1                     |
| 17–39                      | 0.124               | 2.562                 | 0.098                 | 2.765 (0.827–9.243) |
| 40–60                      | 0.037*              | 3.47 (1.075–11.202)   | 0.027*                | 3.81 (1.163–12.486) |
| >60                        | 0.001*              | 7.381 (2.323–23.45)   | 0.004*                | 5.688 (1.722–18.782) |
| Sex                        | Male                | /                     | 1                     |
| Female                     | 0.276               | 0.840 (0.613–1.150)   | 1                     |
| Decade of diagnosis        | 1970s               | /                     | 1                     |
|                            | 1980s               | 0.938                 | 0.977 (0.552–1.731)   | 1                     |
|                            | 1990s               | 0.204                 | 1.444 (0.819–2.545)   | 1                     |
|                            | 2000s               | 0.382                 | 0.784 (0.454–1.353)   | 1                     |
|                            | 2010s               | 0.999                 | 1 (0.512–1.954)       | 1                     |
| Race recode                | Other               | /                     | 1                     |
| Black                      | 0.435               | 1.293 (0.679–2.462)   | 1                     |
| Tumor Grade                | Low                 | /                     | 1                     |
| High                       | 0.065               | 1.691 (0.968–2.954)   | 1                     |
| Unknown                    | 0.02*               | 1.97 (1.115–3.48)     | 1                     |
| Tumor type                 | Fibrosarcoma (NOS)  | /                     | 1                     |
| Fibromyxosarcoma           | 0.188               | 0.263 (0.036–1.923)   | 1                     |
| Periosteal fibrosarcoma    | 0.249               | 0.649 (0.311–1.354)   | 1                     |
| Malignant fibrous histiocytoma | 0.609           | 0.906 (0.621–1.322)   | 1                     |
| Tumor Size                 | <5 cm               | /                     | 1                     |
|                            | 0.109               | 1.889 (0.868–4.114)   | 0.034*                | 2.335 (1.065–5.124)  |
|                            | >10                 | < 0.001*              | 4.714 (2.111–10.527)  | 0.001*                | 4.051 (1.769–9.275)  |
|                            | Unknown             | < 0.001*              | 3.301 (1.602–6.801)   | 0.027*                | 2.324 (1.14–4.91)    |
| Tumor sequence             | First               | /                     | 1                     |
|                            | ≥Second             | 0.031*                | 1.616 (1.045–2.505)   | 1                     |
| Stage                      | Local               | /                     | 1                     |
|                            | region              | 0.128                 | 1.355 (0.916–2.004)   | 0.091                 | 1.421 (0.945–2.135)  |
|                            | distant             | < 0.001*              | 5.383 (3.517–8.237)   | < 0.001*              | 3.917 (2.427–6.321)  |
|                            | unknown             | < 0.001*              | 2.68 (1.468–4.892)    | 0.515                 | 1.239 (0.65–2.359)   |
| Surgery                    | No                  | /                     | 1                     |
|                            | Yes                 | < 0.001*              | 0.267 (0.19–0.376)    | < 0.001*              | 0.397 (0.262–0.6)    |
|                            | unknown             | 0.408                 | 0.433 (0.063–1.344)   | 0.528                 | 0.515 (0.066–4.05)   |
| Radiotherapy               | no/unknown          | /                     | 1                     |
|                            | Yes                 | 0.003*                | 1.684 (1.196–2.371)   | 0.831                 | 0.959 (0.655–1.404)  |
| Chemotherapy               | no/unknown          | /                     | 1                     |
|                            | Yes                 | 0.023*                | 0.688 (0.499–0.949)   | 0.282                 | 0.816 (0.563–1.182)  |

Abbreviations: OS Overall survival, SEER Surveillance, epidemiology, and end results

*p < 0.05
Survival by radiotherapy and chemotherapy

Radiotherapy was used as an adjunct to surgical management in patients with positive margins [22]. In the univariate analysis of OS, radiotherapy (RT) was associated with poor CSS (HR was 1.652 (p = 0.02)) and OS (HR was 1.684 (p = 0.003)). The results were consistent with a recent study [15]. This may be caused by the selection bias of patients with radiotherapy. Chemotherapy was

| Variables                  | Univariate analysis | p-value | Hazard ratio (95% CI) | Multivariate analysis | p-value | Hazard ratio (95% CI) |
|----------------------------|---------------------|---------|-----------------------|-----------------------|---------|-----------------------|
| Age                        | ≤16                 | /       | 1                     | /                     | 1       | /                     |
|                            | 17–39               | 0.192   | 2.243 (0.666–7.554)   | 0.1                   | 2.803   | (0.822–9.556)         |
|                            | 40–60               | 0.206   | 2.153 (0.655–7.074)   | 0.183                 | 2.271   | (0.679–7.601)         |
|                            | >60                 | 0.032*  | 3.569 (1.112–11.454)  | 0.03*                 | 3.863   | (1.14–13.091)         |
| Sex                        | Male                | /       | 1                     | /                     | 1       | /                     |
|                            | Female              | 0.427   | 0.854 (0.578–1.261)   | /                     | 1       | /                     |
| Decade of diagnosis        | 1970s               | /       | 1                     | /                     | 1       | /                     |
|                            | 1980s               | 0.82    | 1.088 (0.526–2.249)   | /                     | 1       | /                     |
|                            | 1990s               | 0.447   | 1.323 (0.643–2.72)    | /                     | 1       | /                     |
|                            | 2000s               | 0.358   | 0.726 (0.367–1.437)   | /                     | 1       | /                     |
|                            | 2010s               | 0.514   | 0.755 (0.324–1.759)   | /                     | 1       | /                     |
| Race recode                | Other               | /       | 1                     | /                     | 1       | /                     |
|                            | White               | 0.853   | 1.076 (0.497–2.329)   | /                     | 1       | /                     |
|                            | Black               | 0.28    | 1.633 (0.671–3.974)   | /                     | 1       | /                     |
| Tumor Grade                | High                | /       | 1                     | /                     | 1       | /                     |
|                            | Low                 | 0.101   | 1.859 (0.885–3.905)   | /                     | 1       | /                     |
|                            | Unknown             | 0.06    | 2.079 (0.896–4.464)   | /                     | 1       | /                     |
| Tumor type                 | Fibrosarcoma (NOS)  | /       | 1                     | /                     | 1       | /                     |
|                            | Fibromyxosarcoma    | 0.436   | 0.45 (0.061–3.351)    | /                     | 1       | /                     |
|                            | Periosteal fibrosarcoma | 0.571 | 0.754 (0.284–2.004)   | /                     | 1       | /                     |
|                            | Malignant fibrous histiocytoma | 0.864 | 1.043 (0.643–1.693)   | /                     | 1       | /                     |
| Tumor Size                 | <5 cm               | /       | 1                     | /                     | 1       | /                     |
|                            | 5 cm-10             | 0.163   | 1.446 (0.861–2.426)   | 0.205                 | 1.908   | (0.703–5.176)         |
|                            | >10                 | < 0.001*| 7.595 (4.553–12.671)  | 0.033*                | 3.075   | (1.092–8.659)         |
|                            | Unknown             | 0.08    | 2.108 (0.914–4.863)   | 0.082                 | 2.314   | (0.899–5.951)         |
| Tumor sequence             | First               | /       | 1                     | /                     | 1       | /                     |
|                            | ≥Second             | 0.023*  | 0.042 (0.003–0.641)   | 0.943                 | 0       | /                     |
| Stage                      | local               | /       | 1                     | /                     | 1       | /                     |
|                            | region              | 0.128   | 1.355 (0.916–2.004)   | 0.145                 | 1.481   | (0.873–2.514)         |
|                            | distant             | < 0.001*| 5.383 (3.517–8.237)   | < 0.001*              | 4.401   | (2.47–7.841)          |
|                            | unknown             | < 0.001*| 2.68 (1.468–4.892)    | 0.942                 | 0.967   | (0.396–2.363)         |
| Surgery                    | No                  | /       | 1                     | /                     | 1       | /                     |
|                            | Yes                 | < 0.001*| 0.226 (0.15–0.34)     | < 0.001*              | 0.318   | (0.191–0.527)         |
|                            | unknown             | 0.963   | 0.989                 | 0                     | 1       | /                     |
| Radiotherapy               | no/unknown          | /       | 1                     | /                     | 1       | /                     |
|                            | Yes                 | 0.02*   | 1.652 (1.084–2.517)   | 0.589                 | 0.878   | (0.546–1.409)         |
| Chemotherapy               | no/unknown          | /       | 1                     | /                     | 1       | /                     |
|                            | Yes                 | 0.481   | 0.87 (0.59–1.282)     | 0.871                 | 0.963   | (0.609–1.523)         |

Abbreviations: CSS Cancer-specific survival, SEER Surveillance, epidemiology, and end results

*p < 0.05
also an important adjuvant therapy. In the multivariate analysis of OS and CSS, we did not find that chemotherapy was an independent prognostic factor for OS and CSS. However, a previous study demonstrated that clinical factors were associated with radiotherapy only in nonmetastatic malignant fibrous histiocytoma (MFH) of soft tissues [1].

Survival for tumour type and tumour sequence
Tumour type was not an independent prognostic indicator for OS or CSS in multivariate analysis. In addition, tumour sequence was an independent prognostic indicator of OS and CSS, suggesting that patients with second primary bone MFN in their long bones may have a worse prognosis than those with a first primary tumour. The patients’ number of more than 2 sequence was as low as 29, among which 12 in fibrosarcoma, 17 in malignant fibrous histiocytoma. This leads to the difficulty in analyzing in multivariate analysis. Therefore, the results of tumour sequence should be taken into consideration carefully.

Survival by tumour size
For smaller tumours with no evidence of metastasis, surgical extirpation alone may be the definitive treatment [16, 23]. Our study showed that tumour size > 10 cm was a prognostic factor for both poor OS and CSS, which was consistent with a recent study [16].

Survival for stage and surgery
Stage and surgery have been previously recognized as predictors of survival in patients with malignant bone tumours [24–26]. These factors were also independent predictors of OS and CSS in the study. MFN was highly metastatic tumour. Therefore, surgical removal of the primary tumour and distant lesions should be addressed and may be applicable to prolong survival in patients with MFN of the long bones and metastasis at diagnosis. Surgery remains the primary treatment strategy for MFN. Patients treated with this strategy had the best OS.
and CSS. Finally, there was not significant difference between upper limbs and lower limbs (data not shown).

Strengths and limitations
This study is a population-based, with high-quality data, and the largest ever published on this category of rare tumours. However, this study has several limitations. These include the fact that there were no data on surgical type, node status, and RT dose.

Conclusion
This is the largest population-based study to show demographics and analyse the prognosis of patients with MFN of the long bones. Independent predictors of OS included age, stage, tumour size and surgery. Age, stage, tumour size and surgery were also independent predictors of CSS. The results of this study may improve doctors’ understanding of the features and outcomes of MFN of the long bones. It may also be useful for patient health education and to provide a foundation for future research.

Abbreviations
CK: Cytokeratin; CSS: Cancer-specific survival; GCT: Giant cell tumour; LBFS: Fibrosarcoma of long bone; MFH: The malignant fibrous histiocytoma; MFN: Malignant fibrous neoplasms; mo: Months; NA: Not available; NED: No evidence of disease; NSAIDs: Non-steroidal anti-inflammatory drugs; OS: Overall survival; PVNS: Pigmented villonodular synovitis; ROM: Range of motion; SC: Synovial chondromatosis; SEER: The Surveillance, Epidemiology, and End Results; SMA: Smooth muscle actin; yr: Years

Acknowledgements
The authors thank Zexin Chen for teaching us about data analysis.

Authors’ contributions
WW and YH wrote the draft of the manuscript. JH, JM and HW read the pathological results and prepared the figures. MS and SY analysed the data and prepared the tables. All authors read and approved the final manuscript.

Funding
National Natural Science Foundation of China (NO. 81602312) funded the design of the study. Zhejiang Province Natural Science Foundation (NO. LQ18H060001 and NO. LY17H060004) funded the collection, analysis, and interpretation of data. Zhejiang Province Medical and Health project (NO. 2018269731) and Zhejiang Province Chinese Medicine Project (NO. 2015ZB028) funded the writing and revising of this manuscript.
Availability of data and materials
The public can obtain the raw data from the author by emailing Yiting Huang.

Ethics approval and consent to participate
Not applicable.

Consent for publication
The authors have obtained the patient’s written informed consent for print and electronic publication of this case report.

Competing interests
The authors declare that they have no competing interests.

Author details
1Division of Reproductive Medicine & Infertility, The Second Affiliated Hospital, Zhejiang University School of Medicine, No.88 Jiefang Road, Hangzhou 310009, People’s Republic of China. 2Department of Orthopaedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, No.88 Jiefang Road, Hangzhou 310009, People’s Republic of China.

Received: 17 December 2018 Accepted: 26 November 2019

References
1. Belal A, Kandil A, Allam A, Khaifa Y, El-Husseiny G, Memon M, Younge D, Moreau P, Gray A, et al. Malignant fibrous histiocytoma: a retrospective study of 109 cases. Ann J Clin Oncol. 2002;25(1):116–22.
2. Hefner DK, Gnepp DR. Sinonasal fibrosarcomas, malignant schwannomas, and “triton” tumors. A clinicopathologic study of 67 cases. Cancer. 1992; 70(5):1089–101.
3. Ozsello L, Stout AP, Murray MR. Cultural characteristics of malignant histiocytomas and fibrous xanthomas. Cancer. 1962;16:331–44.
4. Kauffman SL, Stout AP. Histiocytic tumors (fibrous xanthoma and histiocytoma) in children. Cancer. 1961;14:469–82.
5. Simons A, Schepens M, Jeuken J, Sprenger S, van de Zande G, Bjerkehagen B, Forus A, Weibolt V, Molenaar I, van den Berg E, et al. Frequent loss of 9p21 (p16/INK4A) and other genomic imbalances in human malignant fibrous histiocytoma. Cancer Genet Cytogenet. 2000;118(2):89–98.
6. Fu YS, Perzin KH. Nonepithelial tumors of the nasal cavity, paranasal sinuses, and nasopharynx. VI. Fibrous tissue tumors (fibroma, fibromatosis, fibrosarcoma). Cancer. 1976;37(6):2912–28.
7. Ozkut B, Basarin K, Yildiz YH, Kalem M, Saglik Y. Primary malignant fibrous histiocytoma of long bones: long-term follow-up. Eklem Hastalik Cerrahisi. 2016;27(2):94–9.
8. Niu Q, Lu Y, Xu S, Shi Q, Guo B, Guo Z, Huang T, Wu Y, Yu J. Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study. Cancer Manag Res. 2018;10:4479–89.
9. Ge LP, Liu XY, Xiao Y, Gou ZC, Zhao S, Jiang YZ, Di GH. Clinicopathological characteristics and treatment outcomes of occult breast cancer: a SEER population-based study. Cancer Manag Res. 2018;10:4381–91.
10. Wu G, Wu J, Wang B, Zhu X, Shi X, Ding Y. Importance of tumor size at diagnosis as a prognostic factor for hepatocellular carcinoma survival: a population-based study. Cancer Manag Res. 2018;10:4401–10.
11. Pan Y, Lu L, Chen J, Zhong Y, Dai Z. Analysis of prognostic factors for survival in patients with primary spinal chordoma using the SEER registry from 1973 to 2014. J Orthop Surg Res. 2018;13(1):76.
12. Ren S, Wang Z, Huang X, Sun L, Shao J, Ye Z. Prognostic factors for postoperative survival among patients with rhabdomyosarcoma of the limbs. Cancer Manag Res. 2018;10:4181–9.
13. Patel TD, Camilo ET, Vazquez A, Baredes S, Liu JK, Eloy JA. Sinonasal fibrosarcoma: analysis of the surveillance, epidemiology, and end results database. Int Forum Allergy Rhinol. 2016;6(2):201–5.
14. Rubio GA, Alvarado A, Gerth DJ, Tashiro J, Thaller SR. Incidence and outcomes of Dermatofibrosarcoma Protuberas in the US pediatric population. J Craniofac Surg. 2017;28(1):182–4.
15. Tseng WH, Martinez SR, Do L, Tamurian RM, Borys D, Canter RJ. Lack of survival benefit following adjuvant radiation in patients with retroperitoneal sarcoma: a SEER analysis. J Surg Res. 2011;168(2):173–80.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions